NCAM1 and neoplasm: To further evaluate whether tumor-infiltrating NK cells might indeed represent an ongoing anti-immunity response in BC, we analyzed the expression of CD56+ NK cells in a panel of human BC samples classified as low- and high-grade NMIBC and MIBC at diagnosis.